HomepageEquitiesUnited StatesNyseMEDNAX, Inc.NewsSummary MD US58502B1061 (MD) Report
MEDNAX, INC. RECONCILIATION OF INCOME (LOSS) FROM CONTINUING OPERATIONS TO ADJUSTED EBITDA FROM CONTINUING OPERATIONS ATTRIBUTABLE TO MEDNAX, INC. (in thousands) (Unaudited) Three Months Ended March 31, 2023 (Loss) income from continuing operations attributable to Mednax, Inc. $ (20,941) Interest expense 11,818 Loss on early extinguishment of debt 57,016 Income tax benefit (7,401) Depreciation and amortization expense 8,769 Transformational and restructuring related expenses 1,421 Adjusted EBITDA from continuing operations attributable to Mednax, Inc.
